Idexx Laboratories Inc /DE last reported quarterly results on Nov 2, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $1.2 billion (+9.9% year over year) and diluted EPS of $4.01. It usually reports 33–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 1, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Feb 2, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 33–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 2, 2026
33 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
1,214
+9.9%
|
317
+15.5%
|
4.01
+17.9%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1,217
+9.7%
|
338
+15.1%
|
4.27
+17.6%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1,141
+14.3%
|
278
+14.7%
|
3.47
+17.2%
|
|
Feb 2, 2026
33 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1,091
+14.3%
|
248
+14.8%
|
3.08
+17.8%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1,105
+13.3%
|
275
+17.9%
|
3.40
+21.4%
|
|
Aug 4, 2025
35 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1,109
+10.6%
|
294
+44.6%
|
3.63
+48.8%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
998
+3.6%
|
243
+3.0%
|
2.96
+5.3%
|
|
Feb 3, 2025
34 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
954
+5.8%
|
216
+11.1%
|
2.62
+13.0%
|
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IDXX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westbrook, ME
- SEC filer status
- Large accelerated filer
- SEC CIK
- 874716
Other In Vitro & In Vivo Diagnostic Substances companies
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.